Ambalalrabhai EnterprisesBOM:500009 -0.90%70 EBITDA Margin % is 13.31% as of Mar. 2026, which is 17% above its 10-year median of 11.38. GuruFocus rates BOM:500009 with a GF Score™ of 70/100 and a GF Value™ of ₹41.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Ambalalrabhai Enterprises ranks better than 51.61% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ambalalrabhai Enterprises EBITDA Margin % Related Terms
Ambalalrabhai Enterprises EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500009 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ambalalrabhai Enterprises's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambalalrabhai Enterprises EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ambalalrabhai Enterprises's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ambalalrabhai Enterprises's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambalalrabhai Enterprises (BOM:500009) has a EBITDA Margin % of 13.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ambalalrabhai Enterprises and its competitors. This is 17% above median its historical median of 11.38. According to the industry distribution chart, Ambalalrabhai Enterprises ranks #465 out of 961 companies in the Drug Manufacturers industry, placing it in the top 48.4%.
Is Ambalalrabhai Enterprises' EBITDA Margin % too high?
Ambalalrabhai Enterprises' current EBITDA Margin % of 13.31% is 17% above median its 10-year median of 11.38. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Ambalalrabhai Enterprises' value of 13.31% is 6.6% above this industry median. Based on the distribution chart, Ambalalrabhai Enterprises ranks #465 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ambalalrabhai Enterprises has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambalalrabhai Enterprises' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ambalalrabhai Enterprises ranks #465 out of 961 companies for EBITDA Margin %. This puts Ambalalrabhai Enterprises in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Ambalalrabhai Enterprises' value of 13.31% is 6.6% above this benchmark. While the company's 10-year median is 11.38 vs. the industry median of 12.49, Ambalalrabhai Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambalalrabhai Enterprises's current EBITDA Margin % of 13.31% is 6.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ambalalrabhai Enterprises and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambalalrabhai Enterprises's current EBITDA Margin % is 13.31%, which is 17% above median its own 10-year median of 11.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambalalrabhai Enterprises stock overvalued right now?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises (BOM:500009) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.67, compared to a current price of ₹30.82 — trading 26% below its estimated fair value. The current EBITDA Margin % is 13.31%, which is 17% above median its 10-year median of 11.38 and 6.6% above the Drug Manufacturers industry median of 12.49. Ambalalrabhai Enterprises' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ambalalrabhai Enterprises (BOM:500009), the current EBITDA Margin % is 13.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambalalrabhai Enterprises (BOM:500009) Overvalued in 2026?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises stock appears to be undervalued.
The current stock price of ₹30.82 is trading 26% below its estimated GF Value™ of ₹41.67.
GuruFocus considers Ambalalrabhai Enterprises to be Modestly Undervalued.
Key valuation signals for BOM:500009:
EBITDA Margin %: 13.31% (17% above median its 10-year median of 11.38)
GF Value™: ₹41.67 vs. price of ₹30.82 (26% below fair value)
Industry Position: 6.6% above the Drug Manufacturers median (#465 of 961)
No single metric tells the full story. See the BOM:500009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambalal Sarabhai Enterprises Ltd is an India-based company engaged in the manufacturing and marketing of Drugs and Formulation. The operating segment of the company is Pharmaceutical Products. It serves domestic as well as International markets.
70GF Score
Get the complete analysis for BOM:500009
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500009 has been successfully added to your 
